Bevacizumab For Retinopathy Of Prematurity: An Update | 13256
Clinical Pharmacology & Biopharmaceutics
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
ROP remains a major cause of childhood blindness worldwide. The smallest, sickest infants develop the most severe cases of
ROP that may not be successfully treated by near confluent laser to the avascular retina (current standard of care). There is
increased survival of very small preterm infants in hospitals with few neonatologists not optimally equipped to monitor oxygen or
inadequate numbers of ophthalmologists to screen and treat ROP.
An understanding of ROP pathogenesis with emphasis on proper timing of administration, knowledge of systemic
pharmacokinetics of available vascular endothelial growth factor inhibitors, evidence of lack of local ocular toxicity utilizing
human histopathology following intravitreal bevacizumab injection, and awareness of possible systemic toxicity related to vascular
thrombosis especially during development in vulnerable preterm infants are essential.
Efficacy was reported for a single dose of intravitreal bevacizumab (IVB) compared to conventional laser therapy (CLT)
in zone I and posterior zone II in the N Engl. J Med 2011;364(7):603-27. Refractive outcomes at age 2 years are available
comparing IVB and CLT in 82% of surviving infants who have not had recurrence or complications requiring intraocular surgery.
Characteristics of recurrence, especially in zone I cases, are predictable, recognizable, and treatable by one additional dose of IVB.
Local complications are largely preventable in the NICU by employing topical anesthesia, restraining the infant appropriately,
attending carefully to sterile technique, fixating the eye securely, and utilizing a needle of appropriate length and gauge. Systemic
complications have not been reported, but long term safety has not been established.
Helen A. Mintz-Hittner, a native Houstonian, received her B.A. at age 20 years from Rice University, her M.D. at age 24 years from Baylor College
of Medicine, and did a pediatric internship and an ophthalmology residency at Baylor College of Medicine Affiliated Hospitals. She is a Clinical
Professor in the Ruiz Department of Ophthalmology and Visual Science. She has published more than 100 peer reviewed articles and recently
traveled four continents to discuss the preliminary and follow-up results of the prospective, stratified, randomized, masked, multi-center clinical trial:
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT-ROP).
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals